SM
BCTX

Sabby Management’s Briacell Therapeutics BCTX Stock Holding History

Sabby Management’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$99.8K – 43
2024
Q1 		$99.8K Hold
2
– – 0.06% 32
2023
Q4 		$197K Buy
+2
New +$1.44K 0.2% 24

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
LCM
LuminArx Capital Management New York $224M AUM
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Sabby Management's BCTX Position: Q2 2026 in Review

Sabby Management increased its Briacell Therapeutics (BCTX) stake by 9.2% in Q2 2026, buying an estimated $25.1K and bringing the position to 80,721 shares worth $262K. The position accounts for 0.24% of the portfolio, ranked #16.

Sabby Management first reported a position in BCTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $1.04M in Q2 2021. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • Sabby Management held 80,721 shares of Briacell Therapeutics worth $262K as of Q2 2026.
  • Sabby Management bought 6,806 Briacell Therapeutics shares in Q2 2026, an estimated $25.1K.
  • Briacell Therapeutics made up 0.24% of Sabby Management's portfolio in Q2 2026, its #16 holding.
  • Sabby Management first reported a position in Briacell Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Sabby Management's Briacell Therapeutics position peaked at $1.04M in Q2 2021.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.